Milton Gedallovich, MD
Gastroenterology · Pembroke Pines, FLNPI 1033153952
Payments from drug & device makers
Across 528 payments — averaging $58.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$22K
- Dova Pharmaceuticals$3K
- Johnson & Johnson$989
- QOL Medical, LLC$883
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$679
- Gilead$473
- plus $3K from 30 others
What the payments were for
- Consulting fees$250%
- Speaking & faculty fees$20,02565%
- Travel & lodging$8603%
- Food & beverage$9,86432%
- Education$2191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 199 | $22,091 |
| Dova Pharmaceuticals | 3 | $2,763 |
| Johnson & Johnson | 54 | $989 |
| QOL Medical, LLC | 56 | $883 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 56 | $679 |
| Gilead | 29 | $473 |
| Madrigal Pharmaceuticals | 12 | $433 |
| Redhill Biopharma Inc. | 14 | $329 |
| Pfizer | 11 | $236 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $201 |
| Ironwood Pharmaceuticals, Inc | 11 | $183 |
| Phathom Pharmaceuticals, Inc. | 4 | $161 |
| Ferring Pharmaceuticals Inc. | 7 | $148 |
| Intercept Pharmaceuticals, Inc. | 6 | $147 |
| Aimmune Therapeutics, Inc. | 2 | $137 |
| Nestle Healthcare Nutrition Inc. | 8 | $136 |
| Regeneron Healthcare Solutions, Inc. | 4 | $111 |
| Lilly USA, LLC | 5 | $103 |
| Sanofi | 4 | $93 |
| Ardelyx, Inc. | 4 | $92 |
| Olympus America Inc. | 4 | $92 |
| Ipsen Biopharmaceuticals, Inc | 4 | $86 |
| Janssen Scientific Affairs, LLC | 2 | $73 |
| Boston Scientific | 3 | $69 |
| Vivus LLC | 2 | $40 |
| Endo Pharmaceuticals Inc. | 2 | $39 |
| Cumberland Pharmaceuticals, Inc. | 2 | $37 |
| Organon | 3 | $34 |
| Bristol Myers Squibb | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Evoke Pharma, Inc. | 1 | $20 |
| Shionogi Inc | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Covidien LP | 1 | $11 |
| Romark Laboratories, LC | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,992 in reported general payments places this provider in the 80th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 26 | $705,614 |
| Humira(Cf) PenAdalimumab | 35 | $327,625 |
| SucraidSacrosidase | 13 | $161,363 |
| Humira(Cf)Adalimumab | 15 | $115,378 |
| LinzessLinaclotide | 67 | $69,063 |
| ZenpepLipase/Protease/Amylase | 17 | $60,147 |
| XifaxanRifaximin | 16 | $48,478 |
| ViberziEluxadoline | 12 | $28,921 |
| Mesalamine ErMesalamine | 34 | $10,320 |
| Mesalamine | 17 | $8,769 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 46 | $7,897 |
| MotegrityPrucalopride Succinate | 12 | $6,881 |
| Sucralfate | 24 | $5,750 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 54 | $3,696 |
| Lansoprazole | 16 | $3,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $989 | $705,61426 claims |
| AbbVieHumira(Cf), Linzess, Viberzi | $22,091 | $213,36394 claims |
| QOL Medical, LLCSucraid | $883 | $161,36313 claims |
| Aimmune Therapeutics, Inc.Zenpep | $137 | $60,14717 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $679 | $48,47816 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $148 | $7,89746 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $201 | $6,88112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Pembroke Pines
- Howard SchwartzTavernier$38.8M
- Guy NeffSarasota$17.6M
- Syed LateefClermont$6.4M
- Jeffrey SchneiderCoral Springs$6M
- Zaid RanaMiami$5.4M
- David NelsonGainesville$5.2M
- Alan WeintraubTampa$4.7M
- Curtis FreedlandNew Port Richey$4.5M
- Paul HellsternCrystal River$4.5M
- Henry LevineOrlando$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.